What is known about this subject
- A high baseline HBV DNA level has always been listed as an exclusion
criterion for PD-1/PD-L1 inhibitor-associated therapy in clinical
trials, regardless of the antiviral strategies.
- HBV reactivation induced by immunosuppressive agents or cytotoxic
chemotherapy is a complication in cancer patients with pre-existing
HBV infection.
- No study has investigated the interaction between HBV infection and
anti-PD-1 in combination with antiangiogenic therapy undergoing
concurrent TAF prophylaxis.